acute inflammatory demyelinating polyneuropathy no lay-term
Conditions
Interventions
Guillain-Barré syndrome
Innate immunity
Leukocytes
Viruses
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Healthy controls: - Age 18 years or older - Written informed consent given by the subject Former GBS patients: - Fulfilling the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS). - Current age 18 years or older - Written informed consent given by the patient;Recurrent GBS patients: - Occurrence of at least two episodes of GBS, as determined by the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS). - Age 18 years - Written informed consent given by the patient
Exclusion criteria
Exclusion criteria: Healthy controls: - No serological evidence for exposure to a virus, as determined by IgG serology for EBV, CMV, HEV or influenza antigens.;All groups: Additional diseases or disorders at time of blood sampling that may influence the endpoints: - autoimmune diseases (like multiple sclerosis, psoriasis, Crohn*s disease, ulcerative colitis, rheumatoid arthritis, SLE and other systemic diseases) - acute and chronic infectious diseases (like infectious mononucleosis, HIV/AIDS) - malignancies (not in remission) Medicines at time of blood sampling that may affect endpoints (i.e. inflammatory processes): - NSAIDs, oral corticosteroids, cyclosporine - Cytostatic compounds - Cytokines (analogues) and biologicals - Intravenous immunoglobulins.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study parameter is the innate response of leukocytes to microbial triggers as determined by the type I interferon production in response to stimulation of Toll-like receptor 3, 7 or 9. | — |
Secondary
| Measure | Time frame |
|---|---|
| The production of other cytokines and the expression of maturation/activation markers will be determined at the cell surface of leukocytes. Additionally, genetic variants that influence the innate response of leukocytes to microbial triggers will be determined. | — |
Countries
The Netherlands
Outcome results
None listed